Veradermics, Inc
MANEDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
4
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
4 upcoming, 0 past
MANE Earnings Report
EPS Est: $-0.58 | FQ end 2026-06
VDPHL01 Phase 2 Est. Readout
Primary completion for VDPHL01 trial (NCT06527365) in Androgenetic Alopecia
Source2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How MANE's past catalysts played out
VDPHL01
Androgenetic Alopecia
VDPHL01 QD
Androgenetic Alopecia (AGA)
VDMN-21 Patch Low Dose
Verruca Vulgaris
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VDPHL01 | Phase 3 | Androgenetic Alopecia | - | - |
VDPHL01 QD | Phase 3 | Androgenetic Alopecia (AGA) | - | - |
VDMN-21 Patch Low Dose | Phase 2 | Verruca Vulgaris | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Veradermics, Inc's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Veradermics, Inc's (MANE) pipeline across Phase 3, Phase 2. Its lead program is VDPHL01 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Veradermics, Inc's next FDA catalyst?→
Veradermics, Inc's (MANE) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MANE biotech catalysts?→
Add MANE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Veradermics, Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.